The presenter of this webinar, Wilhelm Huisinga, Ph.D., received his doctoral degree in mathematics on mathematical concepts of conformation analysis of bio-molecules from the Department of Mathematics and Computer Science at Freie Universität Berlin and has serves as a professor of Mathematical Modelling and Systems Biology at the Institute of Mathematics.
Monoclonal antibodies, which are biotechnologically engineered proteins, have demonstrated their potential in therapies for cancer and other complex diseases. These antibodies have the ability to specifically bind targets, which means they are able to modify specific cellular targets and signaling pathways. Currently, there are various therapeutic proteins on the market that use their binding specificity to inhibit cell surface receptors with critical biologic function. At the same time, many targeted receptor systems also constitute a degradation mechanism for such drugs because binding leads to endocytosis and ultimately degradation of the drug. However, a thorough understanding of the complex interplay between a drug’s pharmacokinetics and its effect is largely missing. Continue reading